Accordingly, stratified, time-aware, and individualized combinations that target upstream triggers (infection control and primary immune disease), midstream platforms (NLRP3/AIM2, GSDMD), and downstream effectors (IL-1 signaling) constitute a rational framework to curb immune-driven cardiovascular injury (Figure 2). This evidence concerns the gene IL1B and infection.